Nasdaq · Pharmaceutical Preparations
21 entities across 13 jurisdictions, 1 in offshore financial centres. Read directly from the company’s own 10-K EX-21 filed 2026-02-26 — see the exhibit.
| Entity | Jurisdiction | Note |
|---|---|---|
| Indivior Canada Ltd | Canada | |
| Indivior Deutschland GmbH | Germany | |
| Indivior España S.L.U. | Spain | |
| Indivior EU Limited | England and Wales | |
| Indivior Europe Limited | Ireland | |
| Indivior France SAS | France | |
| Indivior Global Holdings Limited | England and Wales | |
| Indivior Israel Ltd | Israel | |
| Indivior Italia S.r.l | Italy | |
| Indivior Jersey Finance (2021) Limited | Jersey | offshore centre |
| Indivior Nordics ApS | Denmark | |
| Indivior Pty Ltd | Australia | |
| Indivior Schweiz AG | Switzerland | |
| Indivior South Africa (Pty) Ltd | South Africa | |
| Indivior UK Limited | England and Wales | |
| Indivior UK Finance No1 Limited | England and Wales | |
| Indivior UK Finance No2 Limited | England and Wales | |
| Indivior UK Finance No3 Limited | England and Wales | |
| Indy 1 (UK) Limited | England and Wales | |
| Opiant Pharmaceuticals UK Limited | England and Wales | |
| RBP Global Holdings Limited | England and Wales |
Two standard screens, computed from the XBRL in FY2025 against FY2024. Every test shows the numbers behind it — a score with its inputs hidden is a number you cannot check.
Bankruptcy-risk screen combining working capital, retained earnings, operating income, market value against liabilities, and asset turnover. Above 2.99 is the safe zone; below 1.81 is distress.
| Year | Revenue | Net income | Free cash flow | Gross margin | Shares |
|---|---|---|---|---|---|
| FY2022 | $901.0M | −$44.0M | −$9.0M | 83.1% | 139,000,000 |
| FY2023 | $1.1B | −$129.0M | −$308.0M | 84.1% | 137,000,000 |
| FY2024 | $1.2B | $2.0M | $7.0M | 80.6% | 133,000,000 |
| FY2025 | $1.2B | $210.0M | −$93.0M | 80.2% | 128,000,000 |
9 institutions tracked — 3 added, 6 reduced. Index money added 322,256 shares while active managers cut 563,244.
| Manager | Kind | Shares | Change | Value |
|---|---|---|---|---|
| CITADEL ADVISORS LLC | Hedge fund | 2,869,027 | −836,017 | $117.7M |
| PRICE T ROWE ASSOCIATES INC /MD/ | Active fund | 955,110 | +816,160 | $39.2M |
| JPMORGAN CHASE & CO | Active fund | 269,603 | −270,260 | $11.3M |
| GEODE CAPITAL MANAGEMENT, LLC | Index | 3,159,866 | +234,178 | $129.7M |
| FMR LLC | Active fund | 402,415 | −125,299 | $16.5M |
| MORGAN STANLEY | Active fund | 3,395,702 | −110,115 | $139.3M |
| STATE STREET CORP | Index | 4,992,071 | +88,078 | $204.8M |
| BANK OF AMERICA CORP /DE/ | Active fund | 632,967 | −34,165 | $26.0M |
| WELLINGTON MANAGEMENT GROUP LLP | Active fund | 45,581 | −3,548 | $1.9M |
From 13F filings, which cover institutions managing over $100m and are filed up to 45 days after the quarter ends — so this is a considered position, not a live one, and it is not the whole shareholder register.
Ownership percentages are a vendor aggregate, not a filing — unlike everything else on this page.
Indivior Pharmaceuticals, Inc. files under SIC 2834 — all 50 pharmaceutical preparations companies compared on assets and F-score.
The structure map above is the Corporate Blueprint, and in the desktop it is interactive — click any entity to re-centre the map on it and walk the ownership chain. It sits alongside the screener, the scorecard and the filings lab on one desk, on your machine.
Sourced from SEC EDGAR primary filings. Figures are as reported by the company and are not investment advice. Scores are standard published screens computed from those filings; every input is shown above so you can check the arithmetic.
